PROTOCOL REVIEW AND MONITORING SYSTEM (PRMS) A single Protocol Review and Monitoring System (PRMS) governs all oncology clinical trial protocols across the Consortium partner institutions and assures that cancer-relevant human research is (1) scientifically important and statistically sound; (2) designed appropriately without excluding special populations for non- scientific reason; (3) feasible, with reasonably attainable accrual targets given the available patient population; and (4) supportive of the research mission of the Consortium. The central feature of the PRMS is the Scientific Review Committee (SRC). The PRMS committee structure is responsible for approving protocols that meet its stringent and well-defined criteria. A Research Group Review is required prior to submission to the SRC as part of a two-stage review process and assures that Consortium protocols are of high scientific merit and feasible prior to investing additional institutional resources in development. The SRC evaluates scientific merit, feasibility, prioritization, and progress of all Consortium clinical trial protocols. As part of the Consortium?s trial activation process, SRC approval is required prior to IRB review. Efficient operations and weekly SRC meetings have resulted in a median overall process time of 14 calendar days (10 business days) which has remained consistent since 2015. The PRMS further ensures that during accrual, the scientific rationale for the protocol has remained relevant and that accrual is sufficient to meet the scientific aims of the trial. Since implementation of the updated Low Accrual Policy in FY 2015, the number of reviews and closures increased from 25 trials reviewed and three closures, to 74 reviewed and 24 closed in FY 2018. All protocols approved by PRMS have access to CCSG-supported centralized resources, including Clinical Protocol and Data Management (CPDM) and the Biostatistics Shared Resource (BSR). PRMS has the ultimate authority to close trials that do not demonstrate scientific progress.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015704-45
Application #
9853671
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Blair, Kris M; Mears, Kevin S; Taylor, Jennifer A et al. (2018) The Helicobacter pylori cell shape promoting protein Csd5 interacts with the cell wall, MurF, and the bacterial cytoskeleton. Mol Microbiol 110:114-127
Jeong, Kyoung Sook; Zhou, Jin; Griffin, Stephanie C et al. (2018) MicroRNA Changes in Firefighters. J Occup Environ Med 60:469-474
Appelbaum, Jacob; Wells, David; Hiatt, Joseph B et al. (2018) Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. J Immunother Cancer 6:82
Chozinski, Tyler J; Mao, Chenyi; Halpern, Aaron R et al. (2018) Volumetric, Nanoscale Optical Imaging of Mouse and Human Kidney via Expansion Microscopy. Sci Rep 8:10396
Talarico, Sarah; Korson, Andrew S; Leverich, Christina K et al. (2018) High prevalence of Helicobacter pylori clarithromycin resistance mutations among Seattle patients measured by droplet digital PCR. Helicobacter 23:e12472
Bhatia, Shailender; Miller, Natalie J; Lu, Hailing et al. (2018) Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma. Clin Cancer Res :
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313

Showing the most recent 10 out of 1267 publications